MediXall (MDXL) Net Income towards Common Stockholders (2019 - 2024)
MediXall's Net Income towards Common Stockholders history spans 8 years, with the latest figure at $231219.0 for Q3 2024.
- For Q3 2024, Net Income towards Common Stockholders rose 123.42% year-over-year to $231219.0; the TTM value through Sep 2024 reached -$2.4 million, up 53.29%, while the annual FY2023 figure was -$4.9 million, 31.73% up from the prior year.
- Net Income towards Common Stockholders reached $231219.0 in Q3 2024 per MDXL's latest filing, up from -$563999.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $231219.0 in Q3 2024 to a low of -$2.5 million in Q1 2022.
- Average Net Income towards Common Stockholders over 5 years is -$1.3 million, with a median of -$1.3 million recorded in 2021.
- Peak YoY movement for Net Income towards Common Stockholders: crashed 86.36% in 2022, then surged 123.42% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.0 million in 2020, then grew by 5.86% to -$1.9 million in 2021, then dropped by 0.46% to -$1.9 million in 2022, then grew by 17.62% to -$1.5 million in 2023, then surged by 115.08% to $231219.0 in 2024.
- Per Business Quant, the three most recent readings for MDXL's Net Income towards Common Stockholders are $231219.0 (Q3 2024), -$563999.0 (Q2 2024), and -$564736.0 (Q1 2024).